Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. The document reports that approximately 38,500 US patients are affected by this rare disease, which involves the accumulation of toxic light chains that damage major organs such as the heart, kidneys, and liver. The presentation notes that there are currently no FDA-approved therapies for patients who relapse after first-line treatment, and available second-line therapies demonstrate low complete response rates of 0-10%. Treatment options are limited, often involving the reuse of older drugs with limited efficacy. The presentation references multiple studies to support these findings and emphasizes the need for improved therapeutic options for this patient population. You can access the full presentation through the link below.